| Title |
State of progress in treating cystic fibrosis respiratory disease
|
|---|---|
| Published in |
BMC Medicine, August 2012
|
| DOI | 10.1186/1741-7015-10-88 |
| Pubmed ID | |
| Authors |
Patrick A Flume, Donald R Van Devanter |
| Abstract |
Since the discovery of the gene associated with cystic fibrosis (CF), there has been tremendous progress in the care of patients with this disease. New therapies have entered the market and are part of the standard treatment of patients with CF, and have been associated with marked improvement in survival. Now there are even more promising therapies directed at different components of the pathophysiology of this disease. In this review, our current knowledge of the pathophysiology of lung disease in patients with CF is described, along with the current treatment of CF lung disease, and the therapies in development that offer great promise to our patients. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 33% |
| United States | 1 | 17% |
| Spain | 1 | 17% |
| Australia | 1 | 17% |
| Unknown | 1 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| United States | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 119 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 28 | 23% |
| Student > Master | 24 | 20% |
| Researcher | 14 | 11% |
| Student > Ph. D. Student | 13 | 11% |
| Student > Doctoral Student | 7 | 6% |
| Other | 20 | 16% |
| Unknown | 16 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 26% |
| Agricultural and Biological Sciences | 31 | 25% |
| Biochemistry, Genetics and Molecular Biology | 13 | 11% |
| Nursing and Health Professions | 8 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 15 | 12% |
| Unknown | 18 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2017.
All research outputs
#2,855,308
of 23,996,277 outputs
Outputs from BMC Medicine
#1,758
of 3,644 outputs
Outputs of similar age
#18,725
of 169,734 outputs
Outputs of similar age from BMC Medicine
#28
of 44 outputs
Altmetric has tracked 23,996,277 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,644 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.0. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,734 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.